Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

1期 进行中（已停止招募） NCT04460937

摘要

This phase I trial investigates the side effects and best dose of adavosertib and how well it works when given in combination with radiation therapy in treating patients with esophageal or gastroesophageal junction cancer for which no treatment is currently available (incurable). Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving adavosertib together with radiation therapy kill more tumor cells than radiation therapy alone in treating patients with esophageal and gastroesophageal junction cancer.

Maximum Tolerated Dose (MTD)

After completion of treatment, an average of 3 weeks · milligrams

Number of Adverse Events

From baseline until completion, an average of 6 months · Number of Events

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Ad — Hoffmann-La Roche
• Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 — National Cancer Institute (NCI)
• Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Un — University of Southern California
• Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresecta — National Cancer Institute (NCI)
• Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients — National Cancer Institute (NCI)
• Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poo — ECOG-ACRIN Cancer Research Group

全部试验